Severe Hyponatremic Encephalopathy Induced by Unsupervised "Therapeutic" 3,4-Methylenedioxymethamphetamine Use in a 55-Year-Old Woman: A Diagnostic Pitfall.
Pierre-Henri Woitrin, Pascale Lievens
Cureus May 1, 2026 DOI: 10.7759/cureus.108360 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | 55-year-old woman |
| Topics | MDMA |
| Keywords | 4-Methylenedioxymethamphetamine MDMA Acute hyponatremia Diagnostic bias Emergency medicine Toxic encephalopathy Toxicology |
| Key findings | MDMA-induced hyponatremic encephalopathy can occur in older adults in non-recreational settings, and representativeness bias may lead emergency physicians to miss the diagnosis. |
Abstract
While the clinical archetype of 3,4-methylenedioxymethamphetamine (MDMA) toxicity is traditionally associated with young individuals in nightlife environments, particularly in nightclubs and rave settings, its emerging role in therapeutic research may contribute to increasing unsupervised use. As MDMA gains mainstream attention for its potential mental health benefits, particularly for posttraumatic stress disorder, its use may involve a broader demographic, including older individuals in non-recreational contexts. This transition may create a diagnostic pitfall for emergency physicians, particularly through representativeness bias - the tendency to judge a clinical situation based on similarity to a stereotypical category without regard to underlying base rates. When severe hyponatremia occurs in an older patient during a mundane social setting, toxic etiologies may be overlooked, as the presentation does not match the expected profile of MDMA toxicity typically seen in younger individuals. We report a life-threatening case of MDMA-induced hyponatremic encephalopathy in a 55-year-old woman, occurring in a private domestic setting. The patient developed severe hyponatremia with neurological deterioration following self-directed "therapeutic" MDMA use. This case highlights the need to reconsider the demographic and contextual profile of synthetic drug toxicity in the era of emerging psychedelic-assisted therapy research and underscores the importance of maintaining a broad differential diagnosis for unexplained hyponatremia with altered mental status, regardless of patient age or social context.
Comparable studies
Other case reports and case series on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA Individuals whose deaths were associated with MDMA or MDEA use | 1987 | Case series | n = 5 |
| Pathology of deaths associated with "ecstasy" and "eve" misuse. Young white men aged 20 to 25 who died after using ring-substituted amphetamines (MDMA... | 1996 | Case series | n = 7 |
| 'Eve' and 'Ecstasy' Individuals who died after using MDMA or MDEA | 1987 | Case series | n = 5 |
| A Method of Conducting Therapeutic Sessions with MDMA Clients with clear therapeutic purpose, excluding those with serious functional... | 1998 | Case study | n = 2 |
| Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) Psychiatric patients presenting between 1990 and 1992 whose symptoms developed in the... | 1994 | Case series | n = 13 |
Citations in the library
Cites 5
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration Social Neuroscience June 25, 2009
- MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress Journal of Psychopharmacology March 1, 2006
- Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials. JAMA Network Open November 4, 2024
- The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clinical journal of the American Society of Nephrology : CJASN November 2008